

7. Literaturangaben

1. A' Court C, Garrard CS. Nosocomial pneumonia in the intensive care unit: mechanisms and significance. *Thorax* 1992; 47(6): 465-473
2. Alfieri N, Ramotar K, Armstrong P, Spornitz ME, Ross G, Winnick J, Cook DR. Two consecutive outbreaks of *Stenotrophomonas maltophilia* (*Xanthomonas maltophilia*) in an intensive-care unit defined by restriction fragment-length polymorphism typing. *Infect Control Hosp Epidemiol* 1999; 20(8): 553-556
3. American Thoracic Society: Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement. *Am J Respir Crit Care Med* 1996; 153(5): 1711-1725
4. Antonelli M, Conti G, Rocco M, Bui M, De Blasi RA, Vivino G, Gasparetto A, Meduri GU. A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. *N Engl J Med* 1998; 339(7): 429-435
5. Blahova J, Hupkova-Lesicka M, Krailikova K, Krcmery V Sr. Extended spectrum beta-lactamase reactions in *Stenotrophomonas maltophilia*. *Infection* 1998; 26(3): 187-188
6. Blot S, Vanderwoude K, Blot K, Colardyn F. Prevalence and risk factors for colonisation with gram-negative bacteria in an intensive care unit. *Acta Clin Belg* 2000; 55(5): 249-256
7. Brown RB, Hosmer D, Chen HC, Terres D, Sands M, Bradley S, Opitz E, Szwedzinski D, Opalenik D. A comparison of infections in different ICUs within the same hospital. *Crit Care Med* 1985; 13(6): 472-476
8. Bryson HM, Brogden RN. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. *Drugs* 1994; 47: 506-535
9. Carmeli Y, Samore MH. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of *Stenotrophomonas maltophilia*: a historical cohort study. *Clin Infect Dis* 1997; 24(6): 1131-1134

10. Charalambous C, Swoboda SM, Dick J, Perl T, Lipsett PA. Risk factors and clinical impact of central line infections in the surgical intensive care unit. *Arch Surg* 1998 ; 133(11): 1241-1246
11. Chatelut M, Dournes JL, Chabanon G, Marty N. Epidemiological typing of *Stenotrophomonas (Xanthomonas) maltophilia* by PCR. *J Clin Microbiol* 1995 ; 33(4): 912-914
12. Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D, Jaeschke RZ, Brun-Buisson C. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. *Ann Intern Med* 1998; 129(6): 433-440
13. Craven DE, Steger KA, Barber TW. Preventing nosocomial pneumonia: state of the art and perspectives for the 1990s. *Am J Med* 1991; 91(3B): 44S-53S
14. D'Agata EM, Venkataraman L, DeGirolami P, Samore M. Molecular epidemiology of acquisition of ceftazidime-resistant gram-negative bacilli in a nonoutbreak setting. *J Clin Microbiol* 1997; 35(10): 2602-2605
15. D'Agata EM, Venkataraman L, DeGirolami P, Burke P, Eliopoulos GM, Karchmer AW, Samore MH. Colonisation with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors and rate of infection. *Crit Care Med* 1999; 27(6): 1090-1095
16. Denton M, Kerr KG. Microbiological and clinical aspects of infection with *Stenotrophomonas maltophilia*. *Clin Microbiol Rev* 1998; 11(1): 57-80
17. Denton M, Todd NJ, Kerr KG, Hawkey PM, Littlewood JM. Molecular epidemiology of *Stenotrophomonas maltophilia* isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. *J Clin Microb* 1998; 36(7): 1953-1958
18. Donowitz LG, Wenzel RP, Hoyt JW. High risk of hospital-acquired infection in the ICU patient. *Crit Care Med* 1982; 10(6): 355-357
19. Drancourt M, Bollet C, Raoult D. *Stenotrophomonas africana* sp. nov, an opportunistic human pathogen in Afrika. *Int J Syst Bacteriol.* 1997; 47: 160-163

20. Elting LS, Bodey GP. Septicaemia due to *Xanthomonas* species and non-aeruginosa *Pseudomonas* species: increasing incidence of catheter-related infections. *Medicine* 1990; 69: 296-306
21. Elting LS, Khardori N, Bodey GP, Fainstein V. Nosocomial infection caused by *Xanthomonas maltophilia*: a case-control study of predisposing factors. *Infect Control Hosp Epidemiol* 1990; 11(3): 134-138
22. Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stephan F, Similowski T, Mercat A, Diehl JL, Sollet JP, Tenailon A. Invasive and non-invasive strategies for management of suspected ventilator-associated pneumonia. A randomised trial. *Ann Intern Med* 2000; 132(8): 621-630
23. Fass RJ, Prior RB. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. *Antimicrob. Agents* 1989; 33: 1268-1272.
24. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant *Acinetobacter* species and *Stenotrophomonas maltophilia* as pathogens in seriously ill patients: geographic patterns, epidemiological features and trends over the SENTRY antimicrobial surveillance program (1997-1999). *Clin Infect Dis* 2001; 32 Suppl 2: S104-113
25. Gardner P, Griffin WB, Swartz MN, Kunz LJ. Nonfermentative gram-negative bacilli of nosocomial interest. *Am J Med* 1970; 48(6): 735-749
26. Girou E, Schortgen F, Delclaux C, Brun-Buisson C, Blot F, Lefort Y, Lemaire F, Brochard L. Association of non-invasive ventilation with nosocomial infections and survival in critically ill patients. *JAMA* 2000; 284(18): 2361-2367
27. Girou E, Stephan F, Novara A, Safar M, Fagon JY. Risk factors and outcome of nosocomial infections: results of a matched case-control study of ICU patients. *Am J Respir Crit Care Med* 1998; 157: 1151-1158
28. Gopalakrishnan R, Hawley HB, Czachor JS, Markert RJ, Bernstein JM. *Stenotrophomonas maltophilia* infection and colonisation in the intensive care units of two community hospitals: a study of 143 patients. *Heart Lung* 1999; 28(2): 134-141

29. Grundmann HJ, Towner KJ, Dijkshoorn L, Gerner-Smidt P, Maher M, Seifert H, Vaneechoutte M. Multicenter study using standardized protocols and reagents for evaluation of reproducibility of PCR-based fingerprinting of *Acinetobacter* spp. *J Clin Microbiol* 1997; 35(12): 3071-3077
30. Haley R. The nationwide nosocomial infection rate: a new need for vital statistics. *Am J Epidemiol.* 1985; 121: 159-163
31. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in five european countries. French and portuguese ICU study groups. *JAMA* 1999; 281(1): 67-71
32. Hauer T, Lacour M, Gastmeier P, Schulgen G, Schumacher M, Ruden H, Daschner F. Nosokomiale Infektionen auf Intensivstationen. Eine bundesweite Prävalenzstudie (NIDEP). *Anaesthesist* 1996; 45(12): 1184-1191
33. Heath T, Currie B. Nosocomial and community-acquired *Xanthomonas maltophilia* infection in tropical Australia. *J Hosp Infect* 1995; 30(4): 309-313
34. Horan T, Culver D, Jarvis W. Pathogens causing nosocomial infections. *Antimicrob.Newsletter* 5; 1988: 65-67
35. Hove RA, Wilson MP, Walsh TR, Millar MR. Susceptibility testing of *Stenotrophomonas maltophilia* to carbapenems. *J Antimicrob Chemother* 1997; 40(1): 13-17
36. Hugh R, Leifson E. A description of the type strain of *Pseudomonas maltophilia*. *Int Bull Bacteriol Nomencl Taxon* 1963; 13: 133-138
37. Hugh R, Ryschenkow E. An *Alcaligenes*-like *Pseudomonas* species. *Bacteriol Proc* 1960: 78
38. Hugh R, Ryschenkow E. *Pseudomonas maltophilia*, an *Alcaligenes*-like species. *J Gen Microbiol* 1961; 26: 123-132

39. Hulisz DT, File TM. Predisposing factors and antibiotic use in nosocomial infections caused by *Xanthomonas maltophilia*. *Infect Control Hosp Epidemiol* 1992; 13(8): 489-490
40. Hurr H, Hawley HB, Czachor JS, Markert RJ, McCarthy MC. APACHE II and ISS scores as predictors of nosocomial in trauma patients. *Am J Infect Control* 1999; 27(2): 79-83
41. Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with early-onset vs. late-onset nosokomial pneumonia in the ICU setting. *Chest* 2000; 117(5): 1434-1442
42. Irifune K, Ishida T, Shimoguchi K, Ohtake J, Tanaka T, Morikawa N, Kaku M, Koga H, Kohno S, Hara K. Pneumonia caused by *Stenotrophomonas maltophilia* with a mucoid phenotype. *J Clin Microbiol* 1994; 32(11): 2856-2857
43. Itokazu GS, Quinn JP, Bell-Dixon C, Kahan FM, Weinstein RA. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. *Clin Infect Dis* 1996; 23: 779-784
44. Johanson WG, Pierce AK, Sanford JP. Changing pharyngeal bacterial flora of hospitalized patients. Emergence of gram-negative bacilli. *N Engl J Med* 1969; 281(21): 1137-1140
45. Johanson WG Jr, Pierce AK, Sanford JP, Thomas GD. Nosocomial respiratory infections with gram-negative bacilli. The significance of colonisation of the respiratory tract. *Ann Intern Med* 1972; 77(5): 701-706
46. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. *Chest* 2001; 119(2. Suppl): 397S-404S
47. Jucker B, Harms AH, Zehnder JB. Adhesion of the positively charged bacterium *Stenotrophomonas (Xanthomonas) maltophilia* 70401 to glass and teflon. *J Bacteriol* 1996; 178: 5472-5479

48. Kaul R, Burt JA, Cork L, Dedier H, Garcia M, Kennedy C, Brunton J, Krajden M, Conly J. Investigation of a multiyear critical care unit outbreak due to relatively drug-sensitive *Acinetobacter baumannii*: risk factors and attributable mortality. *J Infect Dis* 1996; 174(6): 1279-1287
49. Kerr K, Anson GJ, Hawkey. Adherence of clinical and environmental strains of *Xanthomonas maltophilia* to plastic material. Abstr. B-339. In: abstracts of the 94th general meeting of the American Society for Microbiology 1994. American Society for Microbiology, Washington D.C.
50. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. *Ann Intern Med* 2001; 134(4): 298-314
51. Kollef MH, Shapiro SD, Silver P, St John RE, Prentice D, Sauer S, Ahrens TS, Shannon W, Baker-Clinkscale D. A randomised, controlled trial of protocol-directed versus physician-directed weaning from mechanical ventilation. *Crit Care Med* 1997; 25(4): 567-574
52. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infection: a risk factor for hospital mortality among critically ill patients. *Chest* 1999; 115(2): 462-474
53. Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. *Chest* 1995; 108(6): 1655-1662
54. Komagata K, Yabuuchi Y, Tamagawa V, Ohya A. *Pseudomonas melangenosa*. Iizuka and Komagata 1963, a later subjective synonym of *Pseudomonas maltophilia* Hugh and Ryschenkow 1960. *Int J Syst Bacteriol* 1974; 24: 242-247
55. Laing FP, Ramotar K, Read RR, Alfieri N, Kureishi A, Henderson EA, Louie TJ. Molecular epidemiology of *Xanthomonas maltophilia* colonization and infection in the hospital environment. *J Clin Microbiol* 1995; 33(3): 513-518
56. Legras A, Malvy D, Quinioux AI, Villers D, Bouachour G, Robert R, Thomas R. Nosocomial infections: prospective survey of incidence in five French intensive care units. *Intensive Care Med* 1998; 24(10): 1040-1046

57. Lode H, Schaberg T. Pneumonie. *Pneumologie* 1996; 50 Suppl 2: 592-594
58. Lode H, Schaberg T, Raffenberg M, Mauch H. Nosocomial pneumonia in the critical care unit. *Infect Crit Care* 1998; 14(1): 119-133
59. Maes M. Fast classification of plant-associated bacteria in the *Xanthomonas* genus. *FEMS Microbiol Lett* 1993; 113: 161-166
60. Manian FA, Meyer L, Jenne J, Owen A, Taff T. Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units. *Infect Control Hosp Epidemiol* 1996; 17(4): 222-226
61. Maningo E, Watanakunakorn C. *Xanthomonas maltophilia* and *Pseudomonas cepacia* in lower respiratory tracts of patients in critical care units. *J Infect* 1995; 31: 89-92
62. Marshall WF, Keating MR, Anhalt JP, Steckelberg JM. *Xanthomonas maltophilia*: an emerging nosocomial pathogen. *Mayo Clin Proc* 1989; 64(9): 1097-1104
63. Marty N. Epidemiological typing of *Stenotrophomonas maltophilia*. *J Hosp Infect* 1997; 36(4): 261-266
64. Morrison AJ Jr., Hoffmann KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial *Pseudomonas maltophilia* in a university hospital. *J Clin Microbiol* 1986; 24: 52-55
65. Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, Wagener MW, Bodey GP, Steckelberg JM. Bacteremia due to *Stenotrophomonas (Xanthomonas) maltophilia*: a prospective, multicenter study of 91 episodes. *Clin Infect Dis* 1996; 22(3): 508-512
66. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. NCCLS document M7-A2. 1988 2nd ed.

67. Nava S, Ambrosino N, Clini E, Prato M, Orlando G, Vitacca M, Brigada P, Fracchina C, Rubini F. Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial. *Ann Intern Med* 1998; 128(9): 721-728
68. Palleroni NJ, Bradbury JF. *Stenotrophomonas*, a new bacterial genus for *Xanthomonas maltophilia* (Hugh 1980) Swings et al. 1983. *Int J Syst Bacteriol* 1993; 43(3): 606-609
69. Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. *Stenotrophomonas maltophilia* meningitis. Report of two cases and review to the literature. *J Neurosurg* 1997; 87(1): 106-108
70. Potgieter PD, Hammond JM. Etiology and diagnosis of pneumonia requiring ICU admission. *Chest* 1992; 101(1): 199-203
71. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National nosocomial infections surveillance system. *Crit Care Med* 1999; 27(5): 887-892
72. Saino Y, Inoue M, Mitsuhashi S. Purification and properties of an inducible cephalosporinase from *Pseudomonas maltophilia* GN12873. *Antimicrob Agents Chemother* 1984; 25(3): 362-365
73. Saino Y, Kobayashi F, Inoue M, Mitsuhashi S. Purification and properties of inducible penicillin beta-lactamase isolated from *Pseudomonas maltophilia*. *Antimicrob Agents Chemother* 1982; 22(4): 564-570
74. Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of *Stenotrophomonas maltophilia* as an important nosocomial pathogen. *J Chemother* 1999; 11(1): 28-33
75. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. *Am J Med* 1991; 91(3B): 72S-75S
76. Schaberg T, Lode H. Diagnostik der nosokomialen Pneumonie. *Dtsch Med Wochenschr* 1997; 122(3): 61-64

77. Schaumann R, Stein K, Eckhardt C, Ackermann G, Rodloff AC. Infections caused by *Stenotrophomonas maltophilia* – a prospective study. *Infection* 2001; 29(4): 205-208
78. Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant *Stenotrophomonas* (*Xanthomonas*) *maltophilia* and *Burkholderia* (*Pseudomonas*) *cepacia*. *J Hosp Infect* 1995; 30. Suppl: 453-464
79. Spencker FB. Antibakterielle Aktivität von Meropenem im Vergleich mit sieben anderen Antibiotika gegenüber Stämmen von *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia* und *Burkholderia cepacia* isoliert von Kindern mit Mukoviszidose. *Zeitschr Antimikrob Antineoplas Chemother* 1997; 15(2/3): 111-114
80. Suilen JG, Pittet D, Siegrist H. *Stenotrophomonas maltophilia*: Aktuelle Realitäten im Spitalmilieu. *Swiss-NOSO* 1999; 6(3): 1-6
81. Sutter VL. Identification of *Pseudomonas* species isolated from hospital environment and human sources. *Appl Microbiol* 1968; 16(10): 1532-1538
82. Swings J, De Vos P, Van den Mooter M, De Ley J. Transfer of *Pseudomonas maltophilia* Hugh 1981 to the genus *Xanthomonas* as *Xanthomonas maltophilia* (Hugh 1981). *Comb nov Int J Syst Bacteriol* 1983; 33: 409-413
83. Tenover FC, Arbeit RD, Goering RV. How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Molecular typing working group of the society for healthcare epidemiology of America. *Infect Control Hosp Epidemiol* 1997; 18(6): 426-439
84. Traub WH, Leonhard B, Bauer D. Antibiotic susceptibility of *Stenotrophomonas* (*Xanthomonas*) *maltophilia*: comparative (NCCLS criteria) evaluation of antimicrobial drugs with the agar dilution and the agar disk diffusion (Bauer-Kirby) tests. *Chemotherapy* 1998; 44(3): 164-173
85. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C. Ventilator-associated pneumonia caused by potentially drug resistant bacteria. *Am J Respir Crit Care Med* 1998; 157(2): 531-539

86. Ulrich JA, Needham GM. Differentiation of *Alcaligenes faecalis* from *Bordetella bronchiseptica* by biochemical and nutritional methods. *J Bacteriol.* 1953; 65: 210-215
87. Van Couwenberghe CJ, Cohen SH, Tang YJ, Gumerlock PH, Silva J Jr. Genomic fingerprinting of epidemic and endemic strains of *Stenotrophomonas maltophilia* (formerly *Xanthomonas maltophilia*) by arbitrarily primed PCR. *J Clin Microbiol* 1995; 33(5): 1289-1291
88. Van Couwenberghe CJ, Farver TB, Stuard H, Cohen SH. Risk factors associated with isolation of *Stenotrophomonas* (*Xanthomonas*) *maltophilia* in clinical specimens. *Infect Control Hosp Epidemiol* 1997; 18(5): 316-321
89. Vartivarian SE, Anaissie EJ, Kiwan EN, Papadakis KA. The clinical spectrum of *Stenotrophomonas* (*Xanthomonas*) *maltophilia* respiratory infection. *Semin Resp Crit Care Med* 2000; 21(4): 349-355
90. Vartivarian SE, Papadakis KA, Anaissie EJ. *Stenotrophomonas* (*Xanthomonas*) *maltophilia* urinary tract infection. A disease that is usually severe and complicated. *Arch Intern Med* 1996; 156: 433-435
91. Villarino ME, Stevens LE, Schable B, Mayers G, Miller JM, Burke JP, Jarvis WR. Risk factors for epidemic *Xanthomonas maltophilia* infection/colonisation in intensive care unit patients. *Infect Control Hosp Epidemiol* 1992; 13(4): 201-206
92. Vincent JL. Microbial resistance: lessons from the EPIC study. European prevalence of infection. *Intensive Care Med* 2000; 26 Suppl 1: S3-8
93. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. EPIC International Advisory Committee. *JAMA* 1995; 274(8): 639-644
94. Watanabe K. Nosocomial infections due to *Stenotrophomonas maltophilia*. *Intern Med* 1999; 38(11): 842-843

95. Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of *Stenotrophomonas maltophilia*. *J Antimicrob Chemother* 2000; 45(3): 363-365
96. Wust J, Auckenthaler R, Breer C, Frei R, Heinzer I, Kamm W. Antibiotic sensitivity of gram-negative bacteria in intensive care units in Switzerland. *Schweiz Med Wochenschr* 1994; 124(39): 1695-1700
97. Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in *Stenotrophomonas maltophilia*: involvement of a multidrug efflux system. *Antimicrob Agents Chemother* 2000; 44(2): 287-293